The approval of Enhertu as a second-line option further establishes the drug’s growing role in breast cancer, where it’s quickly becoming a go-to treatment for the roughly 15% of patients with HER2-positive disease.
First conditionally approved for third-line use in metastatic disease in 2019, Enhertu has now shown it may be able to help in additional settings. The new approval moves Enhertu forward into second-line care, where it’ll challenge Kadcyla — the drug it topped in head-to-head testing.
